# Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes

> **NCT02868177** · PHASE2,PHASE3 · COMPLETED · sponsor: **Valbiotis** · enrollment: 66 (actual)

## Conditions studied

- Prediabetes
- Type 2 Diabetes
- Hypertriglyceridemia
- Obesity
- Disease
- Insulin Resistance

## Interventions

- **DIETARY_SUPPLEMENT:** Totum-63
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT02868177
- **Lead sponsor:** Valbiotis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2019-04
- **Final completion:** 2019-04
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-10-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02868177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02868177, "Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02868177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*